Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

January 30, 2018; 90 (5) Editorial

Caffeine and Parkinson disease

A possible diagnostic and pathogenic breakthrough

David G. Munoz, Shinsuke Fujioka
First published January 3, 2018, DOI: https://doi.org/10.1212/WNL.0000000000004898
David G. Munoz
From the Department of Laboratory Medicine and Pathobiology (D.G.M.), University of Toronto, Canada; and Department of Neurology (S.F.), Fukuoka University, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinsuke Fujioka
From the Department of Laboratory Medicine and Pathobiology (D.G.M.), University of Toronto, Canada; and Department of Neurology (S.F.), Fukuoka University, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Caffeine and Parkinson disease
A possible diagnostic and pathogenic breakthrough
David G. Munoz, Shinsuke Fujioka
Neurology Jan 2018, 90 (5) 205-206; DOI: 10.1212/WNL.0000000000004898

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
354

Share

  • Article
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Most cases of Parkinson disease (PD) over age 50 are sporadic, and twin studies strongly suggest a predominance of environmental over genetic etiologies.1 However, few factors have been found consistently in epidemiologic studies to have major effects, protective in all cases: smoking, urate,2 and caffeine consumption.3 The protective effect of caffeine (found not only in coffee, but also in tea, and some sodas) has been demonstrated in large prospectively followed populations of men, with a dramatic reduction in risk (up to fivefold for persons who drank more than 4 cups of coffee a day). Decaffeinated coffee afforded no protection, pointing to caffeine rather than other substances in coffee or tea as the underlying pharmacologic agent. No such linear relationship is found in women, in whom the protective effects are either nonexistent or U-shaped.4 Caffeine’s protective effect on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)–induced parkinsonism in experimental models is generally considered supportive evidence.5 A randomized controlled trial of caffeine for treatment of PD found improved motor manifestations at 6 weeks in secondary analyses, but not the hypothesized improvement in excessive daytime sleepiness. Caffeine is an antagonist at adenosine 2A receptors (A2A-R) located exclusively in the striatum, and specifically in medium spiny neurons coexpressing D2 dopamine receptors, a critical link in the indirect motor pathway. A plausible model can be proposed by which blockade of adenosine receptors would protect dopaminergic neurons in the substantia nigra from excitotoxic injury.6 Several randomized controlled trials have confirmed the efficacy of istradefylline, a selective A2A-R antagonist, to reduce “off” time and to improve motor manifestations of PD.7 Thus, exploring the mechanisms by which caffeine may protect against PD is a worthwhile endeavor.

Footnotes

  • Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.

  • Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease 218

  • © 2018 American Academy of Neurology
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Study funding
    • Disclosure
    • Footnotes
    • References
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Articles
    Caffeinated clues from epidemiology of Parkinson’s disease
    Alberto Ascherio, Honglei Chen et al.
    Neurology, December 08, 2003
  • Articles
    Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease
    A. Ascherio, H. Chen, M.A. Schwarzschild et al.
    Neurology, March 11, 2003
  • Article
    Prospective study of plasma urate and risk of Parkinson disease in men and women
    Xiang Gao, Éilis J. O'Reilly, Michael A. Schwarzschild et al.
    Neurology, January 13, 2016
  • Article
    Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers
    A metabolomic study
    Grace F. Crotty, Romeo Maciuca, Eric A. Macklin et al.
    Neurology, September 30, 2020
Neurology: 100 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise